Is the SRD5A2 V89L polymorphism associated with severity of disease in men with early onset prostate cancer?
The SRD5A2 leucine isoform appears to be acting in a dose-dependent manner as a significant disease-modifying factor in young men diagnosed with PCa.
These findings suggest that modifications in lipoprotein surface charge alter CSA distribution within the LDL plasma fraction.